Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer
Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief ...
pharmaphorum2d
Ablynx and Sanofi sign potential 2.4bn euro R&D deal
Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...
Medpage Today on MSN3d
People With HIV Can Safely Receive Kidneys From Donors With HIV
Among 198 patients with HIV who received a kidney from a deceased donor, risk of a safety event within a median of 2.2 years was similar between the two groups (adjusted HR 1.00, 95% CI 0.73-1.38), ...
pharmaphorum4d
Sanofi wagers $400m on miRecule muscular dystrophy therapy
bolted on when it acquired Ablynx in a €3.9 billion deal in 2018. The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that ...
University of Surrey5d
Dr Lindsay Broadbent
There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific nanobody, ALX-0171. To characterize the therapeutic potential of ALX-0171, we exploited our ...